Posts by: Alejandra Viviescas

News

The U.S. Food and Drug Administration (FDA) has granted fast track designation to BerGenBio‘s bemcentinib as a treatment for elderly people with acute myeloid leukemia (AML) whose disease has relapsed, ... Read more

October 29, 2019

European Commission Approves Xospata for AML Patients with Certain Genetic Mutation

News

The European Commission has approved Astellas Pharma‘s small molecule inhibitor Xospata (gilteritinib) for the treatment of relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation, the company has ... Read more